CLINICAL TRIALS PROFILE FOR RASAGILINE MESYLATE
✉ Email this page to a colleague
All Clinical Trials for rasagiline mesylate
Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
---|---|---|---|---|---|---|
NCT00104273 ↗ | Rasagiline 1 mg and 2 mg Added to Aricept 10 mg Daily in Patients With Mild to Moderate Alzheimer's Disease (AD) | Completed | Eisai Inc. | Phase 2 | 2004-08-01 | The purpose of this study is to evaluate the safety, tolerability, and efficacy of two dose levels of rasagiline mesylate versus placebo in patients with mild-to-moderate Alzheimer's Disease who are taking Aricept. |
NCT00104273 ↗ | Rasagiline 1 mg and 2 mg Added to Aricept 10 mg Daily in Patients With Mild to Moderate Alzheimer's Disease (AD) | Completed | Teva Branded Pharmaceutical Products R&D, Inc. | Phase 2 | 2004-08-01 | The purpose of this study is to evaluate the safety, tolerability, and efficacy of two dose levels of rasagiline mesylate versus placebo in patients with mild-to-moderate Alzheimer's Disease who are taking Aricept. |
NCT00104273 ↗ | Rasagiline 1 mg and 2 mg Added to Aricept 10 mg Daily in Patients With Mild to Moderate Alzheimer's Disease (AD) | Completed | Teva Pharmaceutical Industries | Phase 2 | 2004-08-01 | The purpose of this study is to evaluate the safety, tolerability, and efficacy of two dose levels of rasagiline mesylate versus placebo in patients with mild-to-moderate Alzheimer's Disease who are taking Aricept. |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for rasagiline mesylate
Condition Name
Clinical Trial Locations for rasagiline mesylate
Trials by Country
Clinical Trial Progress for rasagiline mesylate
Clinical Trial Phase
Clinical Trial Sponsors for rasagiline mesylate
Sponsor Name